Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

A new, late-stage clinical study shows disappointing results for Eli Lilly's weight loss pill Orforglipron. The experimental ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Orforglipron showed clinically meaningful results at 72 weeks, after three doses, in a pool of more than 3000 adults.

Ozempic is linked to a potentially higher risk of vision loss in some studies. Doctors explain how GLP-1 drugs for diabetes and weight loss affect the eyes.

Novo Nordisk's flagship product is semaglutide. Sold under the names Ozempic and Wegovy, it's one of the leading GLP-1 ...

Mounjaro manufacturer Eli Lilly has unveiled the test results of its new oral GLP-1 medication, orforglipron. The obesity pill, which is designed to be taken daily by patients who are severely ...

Are weight loss shots like Ozempic and Wegovy safe long-term? It’s complicated. Some early studies suggest thyroid concerns ...

The Times has amended a headline that incorrectly suggested doctors should monitor patients taking Ozempic injections in ...

Eli Lilly’s experimental oral weight loss pill helped patients lose about 12 percent of their body weight on average in a late-stage trial, the company said Thursday, positive results but still ...